Results from a phase 3 clinical trial, recently published in The Lancet Oncology, present a significant breakthrough in the field of prostate cancer surgery. The NeuroSAFE technique, a novel approach ...

Candy B, Jones L, Williams R, et al. Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic ...

Among patients with prostate cancer who received MRI-guided stereotactic body radiation therapy (SABR), more than 80% demonstrated “classic” neurovascular bundle patterns and over 96% showed more than ...

New research from Edith Cowan University (ECU) has confirmed that erectile dysfunction in patients living with prostate cancer could be significantly improved through regular exercise. Sexual ...

A DRUG that shrinks tumours in patients with untreatable prostate cancer has shown “remarkable” results, scientists have said. The treatment, called VIR-5500, harnesses the body’s ...

The results of the NeuroSAFE PROOF trial, presented at the 2025 European Association of Urology (EAU) Congress in Madrid and published in The Lancet Oncology, raise the prospect of major quality of ...

Most men experience sexual issues, including erectile dysfunction, after prostate cancer treatment. Regular cardiovascular and strength training workouts can significantly improve sexual function, ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

No significant association found between phosphodiesterase type 5 inhibitor use and biochemical recurrence after radical treatment. Oral drugs to treat erectile dysfunction after radical treatment for ...

Erection pills could help reduce stroke risk and increase blood circulation across the body, according to research ...

Men with prostate cancer are being denied NHS access to a treatment used by Lord Cameron, a senior doctor has revealed.